📰 DISPATCH
The study is real. Liu et al. (Clinical Infectious Diseases, 2020) looked back at 76 severe COVID-19 patients in two Wuhan hospitals: 11.1% died among those given thymosin alpha-1 (Tα1) vs 30.0% among those who weren't (p = 0.044). Tα1 also raised T-cell counts and lowered the "exhaustion" markers PD-1 and Tim-3. PubMed 32442287 ↗
Why "cut deaths nearly threefold" is too strong:
"Approved in 35+ countries" refers to Zadaxin (thymalfasin), mainly for hepatitis B/C and as an immune booster with vaccines or chemotherapy — not for COVID-19, and it is not FDA- or EMA-approved.
Bottom line: Tα1 is a real, well-tolerated immune peptide with interesting effects on exhausted T cells, but it is not a proven COVID or sepsis treatment. If you have a serious infection, follow standard care; ask your doctor before adding anything.
Mean change across all participants was 17% (4 mg), 23% (9 mg) and 25% (12 mg). In the treatment-estimated analysis, weight loss reached up to ~30%, versus about 3% on placebo.
Source: New England Journal of Medicine, published September 29, 2026 · DOI 10.1056/NEJMoa2604169
Lilly wants Reta classified as a biologic (like vaccines). FDA disagreed. Federal judge ruled for FDA. Lilly appealed — outcome pending.
Biologic = 12yr monopoly + permanent compounding ban. Lilly wants to stop what happened with Sema & Tirz going generic.
Under the Biologics Price Competition and Innovation Act (BPCIA), biologics receive 12 years of market exclusivity — no biosimilars, no compounding, Lilly sets price with zero competition. This is why Humira cost $84,000/year before biosimilars arrived.
If you have an active research protocol involving Retatrutide, now is the time to ensure your research supply is adequate before the appeal ruling comes down. Compounding pharmacies can still legally produce Reta while the lawsuit is ongoing. Source verified. Source responsibly.
The idea: a lot of what we call aging comes from metabolic problems, muscle loss and worn-out cells. Fix those and you age slower.
Glycine is one of the most abundant amino acids in the body — critical for collagen, sleep, gut lining, detox, and methylation. Most people eating a modern diet are chronically deficient. Research and educational purposes only.
7 types of sihr reference now in the Ruqyah section. B12/K2/D3 stack guide now in Cheat Sheet. For research and educational use only.
GLP-1 receptor agonists suppress TNF-α, IL-6, IL-1β — the primary drivers of autoimmune joint destruction. Researchers are finding significant benefit for rheumatic and autoimmune conditions beyond their primary metabolic indication.
"Peptides cause cancer" is one of the most repeated fears — and one of the least supported by actual biology. The truth is a genuine tug-of-war between competing mechanisms.
Active cancer diagnosis: consult oncologist before any growth-promoting peptides. Healthy individual with no known malignancy: the fear is largely unsupported by evidence. Context, dose, and individual biology are everything. Always verify with bloodwork.
A cheap, unpatentable byproduct of wood pulp manufacturing — penetrates skin instantly, dragging other molecules into the bloodstream. Studied for cancer, brain injury, arthritis, wound healing, and bladder disease. FDA-approved for one condition. Not mainstream because it can't be patented.
⚠ CLEAN SKIN ONLY — it carries whatever is on your skin. Pharmaceutical grade 99.9% only. Industrial grade = toxic impurities delivered straight to tissue.
Most people with Hashimoto's are handed a Levothyroxine prescription and told it's a lifelong condition. What they're not told: the attack is coming from the immune system — and if you address the root cause, driving TPO antibodies toward zero and restoring full thyroid function is achievable. Here's what the research supports.
Source: Trevor Bachmeyer — A protocol combining Retatrutide + KPV + BPC-157 + Thymosin Alpha-1 + Nicotine Patch in an experimental autoimmune thyroiditis (EAT) murine model produced remarkable results over 12 weeks: autoantibody titers reduced by 60%, thyroid histology improved by 55%, TSH/T4 normalized, and inflammation dropped by 50% — with 100% survival and zero adverse effects.
| Outcome | Control | Protocol | Result |
|---|---|---|---|
| Anti-Tg/Anti-TPO (AU/mL) | 450 ± 40 | 180 ± 20 | ↓ 60% *** |
| Thyroid Histology Score (0–4) | 3.2 ± 0.3 | 1.4 ± 0.2 | ↓ 55% *** |
| TNF-α / IL-6 (pg/mL) | 120 ± 11 | 60 ± 6 | ↓ 50% *** |
| TSH / T4 | Abnormal | Normalized ** | ✓ |
| HOMA-IR (Insulin Sensitivity) | 1.82 ± 0.18 | Normalized ** | ↓ 57% |
| ROS / MDA (Oxidative Stress) | High | ROS ↓45% / MDA ↓40% | *** / ** |
Research and educational use only. Not medical advice. Work with a functional medicine physician or endocrinologist open to root-cause protocols, not just TSH management.
| Marker | Concerning | Optimal |
|---|---|---|
| Fasting Insulin | >8 µIU/mL | <5 µIU/mL |
| HOMA-IR | >2.0 | <1.5 |
| Fasting Glucose | >100 mg/dL | <100 mg/dL |
| Triglycerides | >150 mg/dL | <150 mg/dL |
Lilly's Phase 1b: Eloralintide (selective amylin receptor agonist) + Tirzepatide produces bariatric-surgery-level weight loss faster than anything seen in a drug trial.
| Regimen | Wks | Loss |
|---|---|---|
| Placebo + TZP 5mg | 16 | -10.0% |
| Elora 9mg + TZP 5mg | 16 | -20.5% |
| Elora 9mg + TZP 15mg | 32 | -29.0% 🔥 |
Magnesium L-Threonate is the only form of magnesium clinically proven to cross the blood-brain barrier efficiently. At the synapse, magnesium regulates NMDA receptor activity — reducing overactivation, calming neurological noise, and enabling deeper transitions into slow-wave sleep.
Switching between Tirzepatide and Retatrutide isn't simple — different half-lives, receptor profiles, washout windows. Never mix Tirz and Reta. One at a time.
Larazotide — being explored for long COVID at Harvard. Improves tight junction function, reduces "leaky gut," may prevent spike protein from perpetuating systemic inflammation.
BPC-157 + KPV + Larazotide Acetate + Zinc Carnosine — repairing, calming, sealing, protecting.
🔬 NCBI PMC — Larazotide Research ↗ATX304 — oral AMPK activator studied alongside GLP-1s for weight maintenance post-discontinuation + emerging MASLD/fatty liver data. Early-stage — discuss with your doctor.
Combination therapy (Semaglutide + ATX-304) produced greater fat loss during treatment, prevented weight regain after Semaglutide withdrawal, improved glucose tolerance and liver health, and extended survival on a continued high-fat diet in mice.
Dual-action breakdown: pan-AMPK activation + mitochondrial uncoupling. Animal research showed ~21% fat loss in 28 days with lean mass preserved. Compared against BAM-15 and DNP — where it lands on the risk/benefit spectrum.
Not a powerful fat burner — a subtle, synergistic metabolic health tool. Covers 4-day half-life dosing, GI/thermoregulation/lethargy side effects, why muscle hypertrophy gets harder on it, and where it shines stacked with GLP-1s + growth hormone secretagogues.
Intranasal GLP-1s for "pin fatigue," amylin analogues, mitochondrial uncouplers (ATX-304 & BAM-15) real-world dosing experiences, Steve's side-effect-free fat loss stack, and the crew's first nootropic tier list.
DIO mouse model, Endocrine Society 2025: ATX-304 + Semaglutide produced greater weight loss (-27%) than Semaglutide alone, with weight loss attributable entirely to fat mass — no reduction in lean mass. After Semaglutide withdrawal (where lean mass is normally lost too), ATX-304 prevented weight regain without further lean mass loss.
Key nuance: This is muscle preservation, not muscle building — ATX-304 protects the lean mass you already have while cutting fat; it does not drive hypertrophy on its own.
A researcher's self-reported protocol: 150mg ATX-304 split AM/PM, paired with an SS-31 + MOTS-c + SLU-PP-332 mitochondrial protection stack to manage glycogen depletion, lethargy, and muscle flatness at higher doses. Includes a topical BAM-15 observation. Anecdotal — not a clinical protocol.
Developed at Saint Louis University, SLU-PP-332 is an ERRα agonist (not an estrogen modulator, despite the name) that drives mitochondrial biogenesis and fatty-acid oxidation — mechanistically related to ATX-304's AMPK/uncoupling pathway. Preclinical mouse data (50 mg/kg, 28 days) showed fat loss, reversal of fatty liver, and increased endurance-type muscle fibers. Zero human clinical data — the effective mouse dose translates to an infeasible ~4,000mg/day in humans.
Also sold as OS01 / OS04 — an oral AMPK & mitochondrial activator, not a GLP-1 medication itself. Theoretical/early-stage research — discuss with your doctor before combining compounds.
How myostatin inhibition pairs with Tirzepatide to preserve lean muscle during aggressive fat loss. We're all about to be lean here.
Does GLP research cause blindness? Two perspectives on the headlines — one cautious, one reassuring. The risk (Non-Arteritic Ischemic Optic Neuropathy) applies specifically to people with pre-existing diabetic retinopathy or neuropathy. Read both and decide.
The regulatory and supply landscape for Retatrutide is shifting. Here is what we know, what it means for researchers, and how to stay ahead of it.
Science-backed guide to peptides — mechanisms, dosing protocols, stacking strategies, and clinical research. Now available on Amazon.
📖 Get it on Amazon ↗Pep-Pedia — free, searchable encyclopedia covering peptides, mechanisms, research, dosing references.
🧬 Visit Pep-Pedia ↗Three complete guides in one 82-page searchable document: Part 1 — Complete Peptide Reference (80+ compounds). Part 2 — Storage & Shelf Life Guide. Part 3 — Reconstitution Guide.
📥 DOWNLOAD PDF GUIDE ↗Wallet setup, buying coins, sending payment, avoiding mistakes.
Full Tesamorelin research reference — gelling fixes, refrigeration guidance, 10/20/30 dosing protocol, info guide, and reta retest. For research use only.
Peter Magic, founder of Janoshik — the gold standard of independent peptide testing — breaks down sterility testing, heavy metals, endotoxins, and how to spot a fake COA. Required watching before buying from any vendor.
